Triple targeting of Auger emitters using octreotate conjugated to a DNA-binding ligand and a nuclear localizing signal

References

• Adelstein SJ, Kassis AI. 1996. Strand breaks in plasmid DNA following positional changes of Auger-electron-emitting radionuclides. Acta Oncol. 35:797–801.
   PubMed Web of Science ®Google Scholar
• Andersson P, Forssell-Aronsson E, Johanson V, Wangberg B, Nilsson O, Fjalling M, Ahlman H. 1996. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med. 37:2002–2006.
   PubMed Web of Science ®Google Scholar
• Balagurumoorthy P, Xu X, Wang K, Adelstein SJ, Kassis AI. 2012. Effect of distance between decaying (125)I and DNA on Auger-electron induced double-strand break yield. Int J Radiat Biol. 88:998–1008.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Brechbiel MW. 2005. Auger electrons: Lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med. 46:1946–1947.
   PubMed Web of Science ®Google Scholar
• Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, et al. 2006. Internalization of sst2, sst3, and sst5 receptors: Effects of somatostatin agonists and antagonists. J Nucl Med. 47:502–511.
   PubMed Web of Science ®Google Scholar
• Charlton DE, Booz J. 1981. A Monte Carlo treatment of the decay of 125I. Radiat Res. 87:10–23.
   PubMed Web of Science ®Google Scholar
• Charlton DE, Humm JL. 1988. A method of calculating initial DNA strand breakage following the decay of incorporated 125I. Int J Radiat Biol Relat Stud Phys Chem Med. 53:353–65.
   PubMedGoogle Scholar
• Cornelissen B, Waller A, Target C, Kersemans V, Smart S, Vallis KA. 2012. 111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI Res. 2:9.
   PubMed Web of Science ®Google Scholar
• Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. 2007. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 48:1357–1368.
   PubMed Web of Science ®Google Scholar
• Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. 2010. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med. 51:1084–1091.
   PubMed Web of Science ®Google Scholar
• De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, Macke HR, Krenning EP. 1998. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 19:283–288.
   PubMed Web of Science ®Google Scholar
• Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L. 2008. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 23:292–300.
   PubMed Web of Science ®Google Scholar
• Elgqvist J, Frost S, Pouget JP, Albertsson P. 2014. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Front Oncol. 3:324.
   PubMedGoogle Scholar
• Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. 2005. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med. 46:2097–2103.
   PubMed Web of Science ®Google Scholar
• Goodarzi AA, Jeggo P, Löbrich M. 2010. The influence of heterochromatin on DNA double strand break repair: getting the strong, silent type to relax. DNA Repair (Amst). 9:1273–1282.
   PubMed Web of Science ®Google Scholar
• Graham K, Wang Q, Garcia Boy R, Eisenhut M, Haberkorn U, Mier W. 2007. Synthesis and evaluation of intercalating somatostatin receptor binding peptide conjugates for endoradiotherapy. J Pharm Pharm Sci. 10:286s–297s.
   Web of Science ®Google Scholar
• Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. 2000. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 41:1256–1263.
   PubMed Web of Science ®Google Scholar
• Jackson MR, Falzone N, Vallis KA. 2013. Advances in anticancer radiopharmaceuticals. Clin Oncol (R Coll Radiol). 25:604–609.
   PubMed Web of Science ®Google Scholar
• Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A. 2000. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 41:1514–1518.
   PubMed Web of Science ®Google Scholar
• Kalderon D, Roberts BL, Richardson WD, Smith AE. 1984. A short amino acid sequence able to specify nuclear location. Cell. 39:499–509.
   PubMed Web of Science ®Google Scholar
• Karagiannis TC, Lobachevsky PN, Martin RF. 2000. Cytotoxicity of an 125I-labelled DNA ligand. Acta Oncol. 39:681–685.
   PubMed Web of Science ®Google Scholar
• Kassis AI. 2003. Cancer therapy with Auger electrons: Are we almost there? J Nucl Med. 44:1479–1481.
   PubMed Web of Science ®Google Scholar
• Lobachevsky P, Clark GR, Pytel PD, Leung B, Skene C, Andrau L, White JM, Karagiannis T, Cullinane C, Lee BQ, et al. 2016. Strand breakage by decay of DNA-bound 124I provides a basis for combined PET imaging and Auger endoradiotherapy. Int J Radiat Biol. [Epub ahead of print]. doi: 10.3109/09553002.2015.1136852.
   PubMedGoogle Scholar
• Lobachevsky P, Smith J, Denoyer D, Skene C, White J, Flynn BL, Kerr DJ, Hicks RJ, Martin RF. 2012. Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. Int J Radiat Biol. 88:1009–1018.
   PubMed Web of Science ®Google Scholar
• Lobachevsky PN, Martin RF. 2000. Iodine-125 decay in a synthetic oligodeoxynucleotide. II. The role of auger electron irradiation compared to charge neutralization in DNA breakage. Radiat Res. 153:271–278.
   PubMed Web of Science ®Google Scholar
• Lobachevsky PN, Martin RF. 2004. Plasmid DNA breakage by decay of DNA-associated auger emitters: Experiments with 123I/125I-iodoHoechst 33258. Int J Radiat Biol. 80:915–920.
   PubMed Web of Science ®Google Scholar
• Lobachevsky PN, White J, Leung M, Skene C, White J, Martin RF. 2008. Plasmid breakage by (125)I-labelled DNA ligands: Effect of DNA-iodine atom distance on breakage efficiency. Int J Radiat Biol. 84:991–1000.
   PubMed Web of Science ®Google Scholar
• Lomax ME, Folkes LK, O’Neill P. 2013. Biological consequences of radiation-induced DNA damage: Relevance to radiotherapy. Clin Oncol (R Coll Radiol). 25:578–585.
   PubMed Web of Science ®Google Scholar
• Loontiens FG, Regenfuss P, Zechel A, Dumortier L, Clegg RM. 1990. Binding characteristics of Hoechst 33258 with calf thymus DNA, poly[d(A-T)], and d(CCGGAATTCCGG): Multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities. Biochemistry. 29:9029–9039.
   PubMed Web of Science ®Google Scholar
• Makrigiorgos GM, Berman RM, Baranowska-Kortylewicz J, Bump E, Humm JL, Adelstein SJ, Kassis AI. 1992. DNA damage produced in V79 cells by DNA-incorporated iodine-123: A comparison with iodine-125. Radiat Res. 129:309–314.
   PubMed Web of Science ®Google Scholar
• Makrigiorgos GM, Kassis AI, Baranowska-Kortylewicz J, McElvany KD, Welch MJ, Sastry KS, Adelstein SJ. 1989. Radiotoxicity of 5-[123I]iodo-2′-deoxyuridine in V79 cells: A comparison with 5-[125I]iodo-2′-deoxyuridine. Radiat Res. 118:532–544.
   PubMed Web of Science ®Google Scholar
• Martin RF. 1977. Induction of double-stranded breaks in DNA by binding with an 125I-labelled acridine. Int J Radiat Biol Relat Stud Phys Chem Med. 32:491–497.
   PubMed Web of Science ®Google Scholar
• Martin RF, Bradley TR, Hodgson GS. 1979. Cytotoxicity of an 125I-labeled DNA-binding compound that induces double-stranded DNA breaks. Cancer Res. 39:3244–3247.
   PubMed Web of Science ®Google Scholar
• Martin RF, Haseltine WA. 1981. Range of radiochemical damage to DNA with decay of iodine-125. Science. 213:896–898.
   PubMed Web of Science ®Google Scholar
• Martin RF, Holmes N. 1983. Use of an 125I-labelled DNA ligand to probe DNA structure. Nature. 302:452–454.
   PubMed Web of Science ®Google Scholar
• Martin RF, Pardee M. 1985. Preparation of carrier free [125I]iodoHoechst 33258. Int J Appl Radiat Isot. 36:745–747.
   PubMedGoogle Scholar
• Olafsen T, Elgqvist J, Wu AM. 2011. Protein targeting constructs in alpha therapy. Curr Radiopharm. 4:197–213.
   PubMedGoogle Scholar
• Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE. 2007. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imaging. 6:56–67.
   PubMed Web of Science ®Google Scholar
• Reubi JC. 2003. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 24:389–427.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B. 2003. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 30:781–793.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, Laissue JA. 2001. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 28:836–846.
   PubMedGoogle Scholar
• Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ. 1999. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res. 5:383–393.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Hotz G. 1973. The occurrence of double-strand breaks in coliphage T1-DNA by iodine-125 decay. Int J Radiat Biol Relat Stud Phys Chem Med. 24:307–313.
   PubMed Web of Science ®Google Scholar
• Sedelnikova OA, Karamychev VN, Panyutin IG, Neumann RD. 2002. Sequence-specific gene cleavage in intact mammalian cells by 125I-labeled triplex-forming oligonucleotides conjugated with nuclear localization signal peptide. Antisense Nucleic Acid Drug Dev. 12:43–49.
   PubMedGoogle Scholar
• Sedelnikova OA, Luu AN, Karamychev VN, Panyutin IG, Neumann RD. 2001. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for antigene radiotherapy. Int J Radiat Oncol Biol Phys. 49:391–396.
   PubMed Web of Science ®Google Scholar
• Sedelnikova OA, Panyutin IG, Thierry AR, Neumann RD. 1998. Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells. J Nucl Med. 39:1412–1418.
   PubMed Web of Science ®Google Scholar
• Stewart M. 2007. Molecular mechanism of the nuclear protein import cycle. Nat Rev Mol Cell Biol. 8:195–208.
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. 2008. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 8:473–480.
   PubMed Web of Science ®Google Scholar
• Terry SY, Vallis KA. 2012. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Int J Radiat Oncol Biol Phys. 83:1298–1305.
   PubMed Web of Science ®Google Scholar
• Tiensuu Janson E, Eriksson B, Oberg K, Skogseid B, Ohrvall U, Nilsson S, Westlin JE. 1999. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors – evaluation of therapeutic and toxic effects. Acta Oncol. 38:373–377.
   PubMed Web of Science ®Google Scholar
• Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, et al. 2002. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med. 32:110–122.
   PubMed Web of Science ®Google Scholar
• Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. 2009. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 50:936–941.
   PubMed Web of Science ®Google Scholar